The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 35, No. 12, pp. 1535-1539. DOI 10.1345/aph.10369
© 2001 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kelly, J
Right arrow Articles by Fuder, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelly, J
Right arrow Articles by Fuder, H

Research Articles

Warfarin pharmacodynamics unaffected by cilomilast

J Kelly, RD Murdoch, DJ Clark, DM Webber, and H Fuder

OBJECTIVE: To demonstrate a lack of effect of steady-state concentrations of cilomilast, a new oral phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease, on warfarin-induced anticoagulation. METHODS: This 28-day, randomized, double-blind, placebo-controlled, parallel-group study involved 36 healthy men. All volunteers received warfarin once daily on days 1 through 24 of the study. After a standard 5-mg loading dose on days 1 and 2, the warfarin dose was titrated between days 3 and 10 to achieve a stable prothrombin time, expressed as international normalized ratio (INR). Volunteers received either cilomilast 15 mg twice daily or placebo on days 18 through 24. The primary end point was the INR on day 24. RESULTS: On day 24, the mean +/- SEM INR in subjects receiving concurrent warfarin and cilomilast was 1.35 +/- 0.05, compared with 1.38 +/- 0.07 in those receiving concurrent warfarin and placebo. The point estimate (90% CI) for the difference in day 24 INR values between cilomilast and placebo (adjusted for baseline) was 0.02 (90% CI-0.13 to 0.17), which translates to an INR ratio of 1.02 (90% CI 0.91 to 0.13). The 90% confidence interval for the ratio of mean INR (cilomilast:placebo) on day 24 was completely contained within the 25% equivalence range, indicating a lack of interaction between warfarin and cilomilast. The adverse event profiles of warfarin/placebo and warfarin/cilomilast were similar and favorable. CONCLUSIONS: The pharmacodynamics of warfarin are unaffected by coadministration of cilomilast at steady-state concentrations in healthy volunteers.


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
S. D Martina, M. S Ismail, and K. S Vesta
Cilomilast: Orally Active Selective Phosphodiesterase-4 Inhibitor for Treatment of Chronic Obstructive Pulmonary Disease
Ann. Pharmacother., October 1, 2006; 40(10): 1822 - 1828.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. B Karish and J. M Gagnon
The Potential Role of Roflumilast: The New Phosphodiesterase-4 Inhibitor
Ann. Pharmacother., June 1, 2006; 40(6): 1096 - 1104.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. M. Holbrook, J. A. Pereira, R. Labiris, H. McDonald, J. D. Douketis, M. Crowther, and P. S. Wells
Systematic Overview of Warfarin and Its Drug and Food Interactions
Arch Intern Med, May 23, 2005; 165(10): 1095 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. D. Murdoch, B. Zussman, J. P. Schofield, and D. M. Webber
Lack of Pharmacokinetic Interactions Between Cilomilast and Theophylline or Smoking in Healthy Volunteers
J. Clin. Pharmacol., September 1, 2004; 44(9): 1046 - 1053.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2001 by Harvey Whitney Books Company.